Uncertainty in the Regenerative Medicine Market and Demand for Treatments
First written in FY2019. 3 of 4 entries say "Restated". Latest entry: FY2022.
1 other company's latest entry also says "Restated".
- FY2022RestatedAnnual report
「The market for regenerative medicine using autologous adipose-derived stem cells or blood remains in its infancy and is highly uncertain, and depending on the enactment or amendment of laws and regulations and trends in treatment outcomes, the increase in the number of treatments at medical institutions may slow.」
The company continues to describe the early-stage nature of the regenerative medicine market, changes in laws and regulations, and the possibility that treatment outcomes could slow demand growth. - FY2021RestatedAnnual report
「The market for regenerative medicine using autologous adipose-derived stem cells or blood remains in its infancy and is highly uncertain, and depending on the enactment or amendment of laws and regulations and trends in treatment outcomes, the increase in the number of treatments at medical institutions may slow.」
The company continues to describe the early-stage nature of the regenerative medicine market using autologous cells and blood, changes in laws and regulations, and the possibility that treatment outcomes could slow demand growth. - FY2020RestatedAnnual report
「Treatments using autologous adipose-derived stem cells or blood remain in their infancy and are highly uncertain, and depending on the enactment or amendment of laws and regulations and trends in treatment outcomes, the increase in the number of treatments at medical institutions may slow.」
The company continues to describe the early-stage nature of autologous cell and blood treatments under private medical care, changes in laws and regulations, and the possibility that treatment outcomes could slow demand growth. - FY2019First statedAnnual report
「Treatments using autologous adipose-derived stem cells or blood remain in their infancy and are highly uncertain, and depending on the enactment or amendment of laws and regulations and trends in treatment outcomes, the increase in the number of treatments at medical institutions may slow.」
Although market growth forecasts have been presented, the treatments remain in their infancy, and the company states that changes in laws and regulations and treatment outcomes could slow the increase in demand.